Related Experiment Video
Updated: Oct 21, 2025

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
Published on: June 14, 2016
Fibroblast growth factor 21 inhibited inflammation and fibrosis after myocardial infarction via EGR1
Jiamin Li1, Liling Gong1, Ruijie Zhang1
1Department of Pharmacology, State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education, Harbin Medical University, Harbin, 150081, China.
Insights
Fibroblast growth factor 21 (FGF21) reduces cardiac inflammation and fibrosis after heart attack. FGF21 works by regulating the FGFR-EGR1 pathway, improving heart remodeling and function.
Area of Science:
- Cardiovascular Biology
- Regenerative Medicine
- Molecular Cardiology
Background:
- Myocardial fibrosis following myocardial infarction (MI) contributes to adverse ventricular remodeling.
- Fibroblast growth factor 21 (FGF21) is implicated in cardiovascular and metabolic diseases, but its role in post-MI cardiac inflammation and fibrosis is unclear.
Purpose of the Study:
- To investigate the therapeutic effects of FGF21 on cardiac inflammation and fibrosis post-MI.
- To elucidate the underlying molecular mechanisms of FGF21 action in the injured heart.
Main Methods:
- Adult male Sprague-Dawley rats underwent MI and were treated with recombinant human basic FGF21 (rhbFGF21).
- Cardiac function was assessed via echocardiography.
- Cardiac inflammation and fibrosis were evaluated using histological staining (hematoxylin-eosin and Masson's trichrome).
- The role of FGF receptors (FGFRs) and the early growth response protein 1 (EGR1) pathway was examined.
Main Results:
- rhbFGF21 administration improved cardiac function and reduced cardiac inflammation and fibrosis.
- FGF21 treatment led to decreased expression of inflammatory and fibrosis-related factors.
- Blocking FGFRs abolished the beneficial effects of FGF21.
- Oxidative stress-induced downregulation of EGR1 was identified as a key mechanism, contributing to reduced inflammation and fibrosis.
Conclusions:
- FGF21 effectively suppresses cardiac inflammation and fibrosis in post-MI hearts.
- The therapeutic effects of FGF21 are mediated through the FGFR-EGR1 signaling pathway.
- FGF21 represents a potential therapeutic target for mitigating adverse cardiac remodeling after myocardial infarction.
Abstract:
Myocardial fibrosis in post-myocardial infarction is a self-healing process of the myocardium, making ventricular remodelling difficult to reverse and develop continuously. Fibroblast growth factor 21 (FGF21) plays an essential role in cardiovascular and metabolic diseases. However, the effect and mechanism of FGF21 action on cardiac inflammation and fibrosis caused by myocardial injury have rarely been reported. Adult male Sprague-Dawley rats administered with or without recombinant human basic FGF21 (rhbFGF21) were assessed using echocardiography and haematoxylin-eosin and Masson's trichrome staining to determine the cardiac function and cardiac inflammation and fibrosis levels. FGF21 might improve cardiac remodelling, as characterised by a decrease in the expression of a series of inflammatory and fibrosis-related factors. Moreover, when FGF receptors (FGFRs) were blocked, the effects of FGF21 disappeared. Mechanistically, we found that oxidative stress induced the downregulation of early growth response protein 1 (EGR1), which contributed to inflammatory factors and fibrosis reduction in cardiomyocytes treated with H2O2. Collectively, FGF21 effectively suppressed the inflammation and fibrosis in post-infarcted hearts by regulating FGFR-EGR1.
More Related Videos
Related Concept Videos
Introduction to Fibroblasts
Myocarditis I: Introduction
Regulation of Angiogenesis and Blood Supply

